Skip to main content
. 2022 Oct 28;71(43):1384–1385. doi: 10.15585/mmwr.mm7143a3

FIGURE.

The figure is a line graph that shows the courses of oral antiviral COVID-19 therapy dispensed per 100,000 persons by zip code-level social vulnerability in the United States during December 23, 2021–August 28, 2022.

Courses of oral antiviral COVID-19 therapy dispensed per 100,000 persons, by zip code–level social vulnerability — United States, December 23, 2021–August 28, 2022*

* Oral antivirals included nirmatrelvir/ritonavir (Paxlovid) (www.fda.gov/media/155050/download) and molnupiravir (Lagevrio) (www.fda.gov/media/155054/download). Zip codes were classified as having low, medium, or high social vulnerability based on ranking within the lower, middle, and upper tertiles of the Equitable Distribution Index score.